Cargando…
Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma
Immunocheckpoint inhibitor (ICI) therapy has provided significant clinical improvements in the treatment of several malignancies. The purpose of this report is to increase awareness of hypereosinophilia associated with checkpoint inhibitors, a topic that has been rarely reported. Hypereosinophilia m...
Autores principales: | Singh, Navdeep, Lubana, Sandeep Singh, Constantinou, George, Leaf, Andrea N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245658/ https://www.ncbi.nlm.nih.gov/pubmed/32509368 http://dx.doi.org/10.1155/2020/7492634 |
Ejemplares similares
-
Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer
por: Hu, Meng, et al.
Publicado: (2022) -
Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)
por: Ma, Xiaoting, et al.
Publicado: (2021) -
Adrenal Metastasis from Uterine Papillary Serous Carcinoma
por: Lubana, Sandeep Singh, et al.
Publicado: (2016) -
Non-Systemic Vasculitic Neuropathy: An Enigmatic Clinical Entity
por: Lubana, Sandeep Singh, et al.
Publicado: (2015) -
Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2020)